Feed / Theme
Confirmed

Biotech & Tech Innovations

30 names are moving together; 23% are participating in the current session.

Co-movement

Observed intraday paths are not available for this group yet.

Members

TICKERCompanySectorTodayObserved activity
WRBYWarby Parker Inc.Healthcare-0.8%Group member
ACMAECOMIndustrials+0.2%Group member
CXAICXApp Inc.Technology-1.3%Group member
ZYMEZymeworks Inc.Healthcare-4.4%Group member
CYRXCryoPort, Inc.Industrials+2.9%Group member
HOODRobinhood Markets, Inc.Financial Services-2.8%Group member
FFAIFaraday Future Intelligent ElecConsumer Cyclical-10.8%Group member
JMIAJumia Technologies AGConsumer Cyclical+1.1%Group member
MECMayville Engineering Company, IIndustrials+0.7%Group member
FCHLFitness Champs Holdings LimitedConsumer Defensive+0.8%Group member
BWLPBW LPG LimitedEnergy+3.4%Group member
GRRRGorilla Technology Group Inc.Technology-2.2%Group member
XXITwenty One Capital, Inc.Financial Services+1.0%Group member
KTKT CorporationCommunication Services-3.8%Most structurally connected
AVAVAeroVironment, Inc.Industrials-2.6%Group member
ORICOric Pharmaceuticals, Inc.Healthcare-0.8%Group member
SRPTSarepta Therapeutics, Inc.Healthcare-7.6%Group member
USLMUnited States Lime & Minerals,Basic Materials+2.1%Group member
PNRGPrimeEnergy Resources CorporatiEnergy-2.9%Group member
LCIDLucid Group, Inc.Consumer Cyclical-4.7%Group member
COINCoinbase Global, Inc.Financial Services+0.4%Group member
OPYOppenheimer Holdings, Inc.Financial Services-0.4%Group member
PGYPagaya Technologies Ltd.Technology+0.8%Group member
NTESNetEase, Inc.Communication Services-4.4%Group member

Why we believe this

Cohort

30 names

Participation

23% this session

Observed history

1 daily builds

Filing coverage

24/30 members

restructuring

The increase in equity in earnings of joint ventures for the year ended September 30, 2025 compared to the same period in the prior year was primarily due to impairment losses recorded by our AECOM Capital segment in fiscal 2024 that did not repeat in fiscal 2025.

ACM 10-K

credit / rates affecting interest expense

The increase in interest expense for the three and six months ended March 31, 2026 was primarily due to an increase in our interest-bearing liabilities.

ACM 10-Q

restructuring affecting expense

The increase in tax expense for the current period compared to the corresponding period last year was due primarily to the tax impact of an increase in pre-tax income of $207.7 million, a tax benefit of $20.1 million related to deferred tax assets recognized due to legal entity restructuring implemented in the first quarter of fiscal 2025, an increase in tax benefit of $10.2 million related to changes in valuation allowances, a tax benefit of $6.9 million related to an audit settlement in the first quarter of fiscal 2024 that did not repeat in fiscal 2025, and tax expense of $5.5 million related to return to provision adjustments resulting from the filing of the prior year's tax return.

ACM 10-Q

Biotech & Tech Innovations can stay leader-led if ASMB and the next software names fail to join while KT keeps moving.

Connected, outside the group

No high-confidence filing-linked non-members are available for this group yet.

History

Historical cohort observations are not available yet.